RR-M01

N/A

Report date: 2025/10/29 16:49:13
First In Class

Base Information

Drug NameRR-M01
Drug Alias NameRR-M01BM-1901
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Macrophages therapy > Chimeric antigen receptor Macrophages therapy
Mechanisms of ActionAnti-HER2
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesRock Roc Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesRock Roc Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A